Next Generation of Enhanced
T-Cell Therapies
Unlocking the full potential of T-cell therapy for cancer and autoimmune diseases
Our Mission
Carmil Therapeutics’ mission is to develop a novel generation of T-cell therapies with enhanced clinical benefits.
Our first aim is to unlock the treatment of solid cancers and other areas where former generations of T-cell therapies have fallen short.
We also aim to improve the clinical efficacy of therapeutic T cells in hematologic malignancies and to engage in the T-cell therapy revolution in autoimmune diseases.
Our Legacy
Our world-renowned co-founder and Chief Scientific Officer Prof. Bernard Malissen brings over 40 years of pioneering research in T-cell biology. Together, we are at the forefront of the T-cell therapy revolution.
Our SCIENCE
Our scientists have identified a key protein in one of the main T-cell activation mechanisms. By introducing our enhanced version of this protein into T cells, we can significantly boost their activation while maintaining safety through antigen dependency.
LEADERSHIP TEAM
Our leadership team, spearheaded by a pioneer in T-cell biology, brings decades of groundbreaking research and expertise to drive our innovative approach.